These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 28726743)

  • 1. The Effect of N-Terminal Cyclization on the Function of the HIV Entry Inhibitor 5P12-RANTES.
    F Nguyen A; S Schill M; Jian M; J LiWang P
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28726743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of structure, dynamics, and detergent interactions of the anti-HIV chemokine variant 5P12-RANTES.
    Wiktor M; Hartley O; Grzesiek S
    Biophys J; 2013 Dec; 105(11):2586-97. PubMed ID: 24314089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A scalable low-cost cGMP process for clinical grade production of the HIV inhibitor 5P12-RANTES in Pichia pastoris.
    Cerini F; Gaertner H; Madden K; Tolstorukov I; Brown S; Laukens B; Callewaert N; Harner JC; Oommen AM; Harms JT; Sump AR; Sealock RC; Peterson DJ; Johnson SK; Abramson SB; Meagher M; Offord R; Hartley O
    Protein Expr Purif; 2016 Mar; 119():1-10. PubMed ID: 26506568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.
    Nedellec R; Coetzer M; Lederman MM; Offord RE; Hartley O; Mosier DE
    PLoS One; 2011; 6(7):e22020. PubMed ID: 21760945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using glycosaminoglycan/chemokine interactions for the long-term delivery of 5P12-RANTES in HIV prevention.
    Wang NX; Sieg SF; Lederman MM; Offord RE; Hartley O; von Recum HA
    Mol Pharm; 2013 Oct; 10(10):3564-73. PubMed ID: 23859720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration.
    McBride JW; Dias N; Cameron D; Offord RE; Hartley O; Boyd P; Kett VL; Malcolm RK
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES.
    Jin H; Kagiampakis I; Li P; Liwang PJ
    Proteins; 2010 Feb; 78(2):295-308. PubMed ID: 19722264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent chimeric inhibitors targeting two steps of HIV cell entry.
    Zhao B; Mankowski MK; Snyder BA; Ptak RG; Liwang PJ
    J Biol Chem; 2011 Aug; 286(32):28370-81. PubMed ID: 21659523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactions.
    Nakata H; Kruhlak M; Kamata W; Ogata-Aoki H; Li J; Maeda K; Ghosh AK; Mitsuya H
    Antivir Ther; 2010; 15(3):321-31. PubMed ID: 20516552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of 5P12-RANTES, A Candidate Rectal Microbicide, in Human Rectal Lavage.
    Cerini F; Offord R; McGowan I; Hartley O
    AIDS Res Hum Retroviruses; 2017 Aug; 33(8):768-777. PubMed ID: 28177261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
    Guan X; Chaffey PK; Chen H; Feng W; Wei X; Yang LM; Ruan Y; Wang X; Li Y; Barosh KB; Tran AH; Zhu J; Liang W; Zheng YT; Wang X; Tan Z
    Biochemistry; 2018 Jan; 57(1):136-148. PubMed ID: 29202246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arrestin Recruitment to C-C Chemokine Receptor 5: Potent C-C Chemokine Ligand 5 Analogs Reveal Differences in Dependence on Receptor Phosphorylation and Isoform-Specific Recruitment Bias.
    Martins E; Brodier H; Rossitto-Borlat I; Ilgaz I; Villard M; Hartley O
    Mol Pharmacol; 2020 Nov; 98(5):599-611. PubMed ID: 32943494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M; Arya SK
    J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational design of novel HIV-1 entry inhibitors by RANTES engineering.
    Vangelista L; Secchi M; Lusso P
    Vaccine; 2008 Jun; 26(24):3008-15. PubMed ID: 18243436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV.
    Zheng Y; Han GW; Abagyan R; Wu B; Stevens RC; Cherezov V; Kufareva I; Handel TM
    Immunity; 2017 Jun; 46(6):1005-1017.e5. PubMed ID: 28636951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemofiltrate CC chemokine 1[9-74] causes effective internalization of CCR5 and is a potent inhibitor of R5-tropic human immunodeficiency virus type 1 strains in primary T cells and macrophages.
    Münch J; Ständker L; Pöhlmann S; Baribaud F; Papkalla A; Rosorius O; Stauber R; Sass G; Heveker N; Adermann K; Escher S; Klüver E; Doms RW; Forssmann WG; Kirchhoff F
    Antimicrob Agents Chemother; 2002 Apr; 46(4):982-90. PubMed ID: 11897579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structural and functional characterization of CC chemokine CCL14.
    Blain KY; Kwiatkowski W; Zhao Q; La Fleur D; Naik C; Chun TW; Tsareva T; Kanakaraj P; Laird MW; Shah R; George L; Sanyal I; Moore PA; Demeler B; Choe S
    Biochemistry; 2007 Sep; 46(35):10008-15. PubMed ID: 17691823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.
    Olson WC; Rabut GE; Nagashima KA; Tran DN; Anselma DJ; Monard SP; Segal JP; Thompson DA; Kajumo F; Guo Y; Moore JP; Maddon PJ; Dragic T
    J Virol; 1999 May; 73(5):4145-55. PubMed ID: 10196311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.